AMPLIFY-7P Phase 2 randomized study anticipated to complete enrollment in Q4 2024; formal interim analysis of disease-free survival ("DFS") expected in H1 2025Poster presentation at the Society for Im ...
In August 2024, Elicio received a $1.5M grant from the Gastro-Intestinal Research Foundation to support continued development of vaccines targeting p53 and BRAF mutations. In July 2024, a $11.5M ...
In a report released yesterday, Jason McCarthy from Maxim Group maintained a Buy rating on Aprea Therapeutics (APRE – Research Report), ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback